Hematology Laboratory, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Josep Carreras Leukemia Research Institute, Badalona, Spain.
Cytometry B Clin Cytom. 2018 Nov;94(6):950-952. doi: 10.1002/cyto.b.21623. Epub 2018 Jan 19.
The CLLflow score was recently suggested as an improvement over the Moreau score (MS) for the diagnosis and classification of B-cell lymphoproliferative disorders (B-LPD).
We determined the CLLflow score in peripheral blood or bone marrow of a series of cases with an inconclusive immunophenotype, including samples with a MS of 3 (n = 52) and CD5-positive with a score of 2 (n = 38). As controls, B-LPD with a MS of 0-1 (n = 95), CD5-negative score 2 (n = 24), and score 4-5 (i.e., chronic lymphocytic leukemia [CLL], n = 166) were included.
The CLLflow score was positive (suggestive of CLL) in all CLL cases and negative in all MS <2, regardless of CD200-positivity, which occurred in 31% (29/95) of cases. The CLLflow score was positive in 71%, 29%, and 8% of samples with a MS 3, CD5-positive score 2, and CD5-negative score 2, respectively.
Our results suggest that the CLLflow is useful in the differential diagnosis of cases with inconclusive immunophenotype. © 2018 International Clinical Cytometry Society.
CLLflow 评分最近被提议作为对 Moreau 评分（MS）的改进，用于诊断和分类 B 细胞淋巴增殖性疾病（B-LPD）。
我们在一系列免疫表型不确定的病例的外周血或骨髓中确定了 CLLflow 评分，包括 MS 为 3 的样本（n=52）和 CD5 阳性且评分 2 的样本（n=38）。作为对照，MS 为 0-1 的 B-LPD（n=95）、CD5 阴性评分 2（n=24）和评分 4-5（即慢性淋巴细胞白血病 [CLL]，n=166）的 B-LPD 也被包括在内。
所有 CLL 病例的 CLLflow 评分均为阳性（提示 CLL），而所有 MS<2 的病例均为阴性，无论 CD200 是否阳性，这在 31%（29/95）的病例中发生。MS 为 3、CD5 阳性评分 2 和 CD5 阴性评分 2 的样本中，CLLflow 评分分别为阳性的比例为 71%、29%和 8%。
我们的结果表明，CLLflow 有助于对免疫表型不确定的病例进行鉴别诊断。©2018 国际临床细胞化学学会。
